Clinical Trial Update: Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID [Phase 3]

View source ↗

Summary

A Phase 3 randomized, double-blind, placebo-controlled trial evaluating baricitinib for persistent neurologic and cardiopulmonary symptoms in Long COVID is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Long Covid

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: Wes Ely | Conditions: Long COVID, Sars-CoV-2 Infection | Phase 3 | Status: RECRUITING